The REVERSE Study - Stage II Chronic Kidney Disease (CKD) In Cats
OPEN FOR RECRUITMENT
Evidence exists to suggest that aging of the kidney may contribute to the onset and progression of chronic kidney disease (CKD). mTOR inhibition is a known modulator of the aging process and additionally may decrease the formation of fibrosis (scarring) in the kidney. The purpose of this study is to assess the potential benefits of dosing TRIV202 in cats with Stage II CKD.
Register For Trial Today!
We invite you to be a part of something truly meaningful - a pharmaceutical trial that has the potential to improve the lives of pets worldwide. By registering your beloved furry companion for our trial, you are taking a step towards a brighter and healthier future for them and countless other animals.